€13.5m financing round to accelerate proteomics tools and consumables 

PreOmics has raised €13.5 million in a Series B financing round provided by Bruker Corporation, which is expected to broaden the market opportunities for both PreOmics’ platform technologies and Bruker’s  proteomics platform with more complete, automated workflow solutions for academic and clinical researchers, for biomarker discovery and diagnostics companies, as well as for CRO and biopharmaceutical companies. 

Dr. Garwin Pichler, Co-Founder and Managing Director of PreOmics, commented: “We are excited to increase R&D, marketing and sales investments, and are pleased to have Bruker as a collaborator and major investor. Bruker shares our vision for advanced proteomic discovery processes for everyone, and a commitment to accelerate PreOmics’ growth. Our existing and future customers and partners will benefit from accelerated investments at PreOmics and from proteomics solution synergies to extend our product offerings and global presence.” 

Image credit: Towfiqu Barbhuiya

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free